Literature DB >> 14651349

Differentiation of prostate cancer and benign prostatic hyperplasia: the clinical value of 201Tl SPECT--a pilot study.

Ching-Chiang Yang1, Shung-Shung Sun, Chun-Yi Lin, Feng-Ju Chuang, Chia-Hung Kao.   

Abstract

PURPOSE: Thallium-201 (201Tl) is a recognized tumor-imaging agent; however, the usefulness of 201Tl in prostate cancer has not been studied. The purpose of this preliminary study was to evaluate the efficacy of 201Tl single-photon emission computed tomography (SPECT) imaging for differentiating prostate cancer from benign prostatic hyperplasia (BPH).
METHODS: 201Tl pelvic SPECT was performed in 10 patients (aged 64-78 years) with biopsy-proven BPH before transurethral resection of the prostate and 15 patients (aged 65-81 years) with biopsy-proven prostate cancer prior to any therapeutic modality or invasive surgical procedures for treatment of their prostate cancer.
RESULTS: From the 15 patients with prostate cancer, 201Tl pelvic SPECT detected prostate cancer in 13 (86.7%) but not in 2 (13.3%) patients with Gleason scores of 5 (2 + 3). In contrast, all 10 patients with BPH (100.0%) had negative results of 201Tl pelvic SPECT.
CONCLUSION: Our study showed that 201Tl pelvic SPECT scan is very helpful in distinguishing between prostate cancer and BPH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14651349     DOI: 10.1007/bf03006663

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  2 in total

1.  MMP26: A potential biomarker for prostate cancer.

Authors:  Teng Cheng; Fei Li; Rui Wei; Meng-Qin Lv; Yin Zhou; Yun Dai; Yuan Yuan; Gui-Ying Jiang; Ding Ma; Qing-Lei Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

2.  Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.

Authors:  Andrej Jedinak; Adam Curatolo; David Zurakowski; Simon Dillon; Manoj K Bhasin; Towia A Libermann; Roopali Roy; Monisha Sachdev; Kevin R Loughlin; Marsha A Moses
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.